Compare American Homes 4 Rent Class A (AMH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Homes 4 Rent Class A vs Vertex Pharmaceuticals Incorporated — how do they compare? American Homes 4 Rent Class A trades at $33.92 (market cap $12.28B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 10.9× American Homes 4 Rent Class A's market cap, and American Homes 4 Rent Class A pays a 3.87% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| AMH | VRTX | |
|---|---|---|
Market Cap | $12.28B | $134.25B |
Sector | Real Estate | Health |
52-Week High | $35.82 | $529.65 |
52-Week Low | $27.38 | $376.62 |
Enterprise Value | $17.35B | $128.37B |
Dividend Yield | 3.87% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
